Boston, MA 10/15/2014 (wallstreetpr) – Verint Systems Inc.(NASDAQ:VRNT) announced on 14th October that it has been recognized as one of the leaders in the 2014 FinTech Rankings brought out by IDC Financial Insights. IDC in an annual exercise publishes the list of top financial service tech vendors globally. In this year’s report Verint Systems Inc. (NASDAQ:VRNT) has been featured in the Enterprise Top 25 list. IDC analysts have pointed out that the tech firm has continued to increase its foot print across various industry and vertical types in addition to its presence in the financial space, and hence has found its self ranked among the top enterprise technology firms.
Medical devices and diagnostic equipment maker Medtronic, Inc. (NYSE:MDT) announced on 14th October that it has enrolled the first set of patients who would be participating in the “investigational device exemption” tests it plans to conduct for its yet to be unveiled Predictive Low Glucose Management technology. The tests are a precursor to the development of artificial pancreas in the U.S. Labs. The tests are designed to test the safety and efficacy of the continuous glucose monitoring (CGM) system. The device is designed to immediately cease the delivery of insulin into the body, when its sensors detect that the level of sugar and glucose in the blood has dropped down to a tolerable limit. The firm believes that if its device gets FDA approval, it would transform the life style of diabetic patients suffering from hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar).
Commercial-stage drug maker Quotient Limited – Unit (NASDAQ:QTNTU) announced that it has received a series of regulatory approvals, which has resulted in the launch of four new products related to “reagent red cells”. The two of the four new products announced are ALBAcyte® Expanded Rh Negative Antibody Screen and ALBAzyme® Papain Solution Kit.
